These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 23386256

  • 1. Clinical outcomes of different first- and second-generation drug-eluting stents in routine clinical practice: results from the prospective multicenter German DES.DE registry.
    Akin I, Hochadel M, Abdel-Wahab M, Senges J, Richardt G, Schneider S, Tebbe U, Kuck KH, Nienaber CA.
    Clin Res Cardiol; 2013 May; 102(5):371-81. PubMed ID: 23386256
    [Abstract] [Full Text] [Related]

  • 2. Outcome of percutaneous coronary intervention with drug-eluting stents in unprotected left main versus non-left main native coronary artery disease: results from the prospective multicenter German DES.DE registry.
    Akin I, Naber C, Sabin G, Hochadel M, Senges J, Kuck KH, Nienaber C, Richardt G, Tölg R.
    Clin Res Cardiol; 2013 Sep; 102(9):679-86. PubMed ID: 23681360
    [Abstract] [Full Text] [Related]

  • 3. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
    Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
    [Abstract] [Full Text] [Related]

  • 4. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S.
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [Abstract] [Full Text] [Related]

  • 5. Outcomes after differential use of drug-eluting stents in diabetic patients: 1-year results from the DES.DE (Drug-Eluting Stent.DEutschland) registry.
    Akin I, Bufe A, Eckardt L, Reinecke H, Richardt G, Kuck KH, Senges J, Schneider S, Nienaber CA, DES.DE Study Group.
    Catheter Cardiovasc Interv; 2010 Jul 01; 76(1):50-7. PubMed ID: 20578192
    [Abstract] [Full Text] [Related]

  • 6. Two-Year Safety and Efficacy of Biodegradable Polymer Drug-Eluting Stent Versus Second-Generation Durable Polymer Drug-Eluting Stent in Patients With Acute Myocardial Infarction: Data from the Korea Acute Myocardial Infarction Registry (KAMIR).
    Hur SH, Kim IC, Won KB, Cho YK, Yoon HJ, Nam CW, Kim KB, Kim MS, Park J, Rha SW, Chae SC, Kim YJ, Kim CJ, Cho MC, Jeong MH, Ahn YK, Kim HS, Ahn TH, Seung KB, Jang Y, Yoon JH, Seong IW, Hong TJ, Bae JH, Park SJ, KAMIR (Korea Acute Myocardial Infarction Registry) Investigators.
    Clin Cardiol; 2016 May 01; 39(5):276-84. PubMed ID: 27028303
    [Abstract] [Full Text] [Related]

  • 7. Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents.
    Kandzari DE, Leon MB, Meredith I, Fajadet J, Wijns W, Mauri L.
    JACC Cardiovasc Interv; 2013 May 01; 6(5):504-12. PubMed ID: 23602459
    [Abstract] [Full Text] [Related]

  • 8. Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
    Cassese S, Kufner S, Xhepa E, Byrne RA, Kreutzer J, Ibrahim T, Tiroch K, Valgimigli M, Tölg R, Fusaro M, Schunkert H, Laugwitz KL, Mehilli J, Kastrati A.
    Clin Res Cardiol; 2016 Jul 01; 105(7):575-84. PubMed ID: 26689707
    [Abstract] [Full Text] [Related]

  • 9. Gender differences and bleeding complications after PCI on first and second generation DES.
    Wanha W, Kawecki D, Roleder T, Pluta A, Marcinkiewicz K, Morawiec B, Kret M, Pawlowski T, Smolka G, Ochala A, Wojakowski W.
    Scand Cardiovasc J; 2017 Feb 01; 51(1):53-60. PubMed ID: 27471987
    [Abstract] [Full Text] [Related]

  • 10. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E, Mangiacapra F, Peace A, Ntarladimas Y, Conte M, Bartunek J, Vanderheyden M, Wijns W, de Bruyne B, Barbato E.
    Arch Cardiovasc Dis; 2013 Nov 01; 106(11):554-61. PubMed ID: 24231052
    [Abstract] [Full Text] [Related]

  • 11. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F, Romano M, Rosiello R, La Vecchia L, Cabianca E, Caramanno G, Milazzo D, Loschiavo P, Rigattieri S, Musarò S, Pironi B, Fiscella A, Amico F, Indolfi C, Spaccarotella C, Bartorelli A, Trabattoni D, Della Rovere F, Rolandi A, Beqaraj F, Belli R, Sangiorgio P, Villani R, Berni A, Sheiban I, Lopera Quijada MJ, Cappi B, Ribaldi L, Vassanelli C, EXECUTIVE Trial Investigators.
    JACC Cardiovasc Interv; 2013 Oct 01; 6(10):1012-22. PubMed ID: 24055444
    [Abstract] [Full Text] [Related]

  • 12. Long-term clinical outcome of rotational atherectomy followed by drug-eluting stent implantation in complex calcified coronary lesions.
    Abdel-Wahab M, Baev R, Dieker P, Kassner G, Khattab AA, Toelg R, Sulimov D, Geist V, Richardt G.
    Catheter Cardiovasc Interv; 2013 Feb 01; 81(2):285-91. PubMed ID: 22431433
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness of everolimus-eluting stents in the treatment of drug-eluting stent versus bare-metal stent restenosis.
    Almalla M, Pross V, Marx N, Hoffmann R.
    Coron Artery Dis; 2012 Nov 01; 23(7):492-6. PubMed ID: 22990414
    [Abstract] [Full Text] [Related]

  • 14. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
    Rodriguez AE, Rodriguez-Granillo AM, Antoniucci D, Mieres J, Fernandez-Pereira C, Rodriguez-Granillo GA, Santaera O, Rubilar B, Palacios IF, Serruys PW, ORAR III Investigators.
    Catheter Cardiovasc Interv; 2012 Sep 01; 80(3):385-94. PubMed ID: 22109997
    [Abstract] [Full Text] [Related]

  • 15. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G, Leschke M, Abdel-Wahab M, Toelg R, El-Mawardy M, Serruys PW, Silber S, Windecker S, Belardi JA, Neumann FJ, Widimsky P, RESOLUTE All Comers, RESOLUTE International Investigators.
    JACC Cardiovasc Interv; 2013 Sep 01; 6(9):905-13. PubMed ID: 23954063
    [Abstract] [Full Text] [Related]

  • 16. Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions).
    Azzalini L, Giustino G, Ojeda S, Serra A, La Manna A, Ly HQ, Bellini B, Benincasa S, Chavarría J, Gheorghe LL, Longo G, Miccichè E, D'Agosta G, Picard F, Pan M, Tamburino C, Latib A, Carlino M, Chieffo A, Colombo A.
    Circ Cardiovasc Interv; 2016 Oct 01; 9(10):. PubMed ID: 27765802
    [Abstract] [Full Text] [Related]

  • 17. Comparison between sirolimus- and paclitaxel-eluting stents for the treatment of older patients affected by coronary artery disease: results from a single-center allcomers registry.
    Buja P, Lanzellotti D, Isabella G, Napodano M, Panfili M, Favaretto E, Iliceto S, Tarantini G.
    Heart Vessels; 2012 Nov 01; 27(6):553-8. PubMed ID: 21989862
    [Abstract] [Full Text] [Related]

  • 18. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT, Sun H, Zhang DP, Xu L, Ni ZH, Xia K, Liu Y, Chi YH, He JF, Li WM, Wang HS, Wang LF, Yang XC.
    Coron Artery Dis; 2014 Aug 01; 25(5):405-11. PubMed ID: 24584031
    [Abstract] [Full Text] [Related]

  • 19. Comparison of the efficacy and safety of paclitaxel-eluting coroflex please stents and paclitaxel-eluting stents in patients with coronary artery disease: a randomized PIPA trial.
    Kim HS, Park SJ, Park DW, Park SW, Cheong SS, Lee SG, Cho BR, Lee SW, Lee NH, Lee K, PIPA Study Investigators.
    Catheter Cardiovasc Interv; 2012 Nov 01; 80(5):799-806. PubMed ID: 22120995
    [Abstract] [Full Text] [Related]

  • 20. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW, Lee JM, Kang SH, Ahn HS, Kang HJ, Koo BK, Rhew JY, Hwang SH, Lee SY, Kang TS, Kwak CH, Hong BK, Yu CW, Seong IW, Ahn T, Lee HC, Lim SW, Kim HS.
    JACC Cardiovasc Interv; 2014 May 01; 7(5):471-81. PubMed ID: 24852802
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.